GenSight Biologics S.A. (SIGHT.PA)

3.55 €

+0.03 (+0.74%)
Rating:
Recommendation:
-
Symbol SIGHT.PA
Price 3.55 €
Beta 2.420
Volume Avg. 0.09M
Market Cap 163.876M
Shares () -
52 Week Range 1.802-6.135
1y Target Est -
DCF Unlevered SIGHT.PA DCF ->
DCF Levered SIGHT.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 1165.19% Strong Buy
P/E -5.61 Strong Sell
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Bernard Gilly
Healthcare
Biotechnology
Paris

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.